Topoisomerase I
6 drugs Oncology
5
approved indications
6
Approved Drugs
6
Companies
12
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (6 companies)
✓ All 6 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (12 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
DAIICHI SANKYO 1 drug
QILU PHARM HAINAN 1 drug
DAIICHI SANKYO INC 1 drug
By Therapeutic Area
Oncology 4 drugs
Other 2 drugs
By Therapeutic Area
Oncology 4 drugs
IRINOTECAN HYDROCHLORIDE, DATROWAY, CAMPTOSAR, HYCAMTIN
Other 2 drugs
ENHERTU, TRODELVY
Indications Treated
Colon CancerRectal CancerUnresectable or metastatic HER2-positive breast cancerUnresectable or metastatic hormone receptor-positive, HER2-low or HER2-ultralow breast cancerUnresectable or metastatic HER2-low breast cancerUnresectable or metastatic HER2-mutant non-small cell lung cancerLocally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinomaNon-Small Cell Lung CancerBreast CancerSmall Cell Lung CancerUnresectable locally advanced or metastatic triple-negative breast cancer (mTNBC)Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer